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Abstract 
Cyclopentenone prostaglandins (cyPG) are endogenous lipid mediators involved in the 
resolution of inflammation and the regulation of cell proliferation and cellular redox status. 
Upon exogenous administration they have shown beneficial effects in models of inflammation 
and tissue injury, as well as potential antitumoral actions, which have raised a considerable 
interest in their study for the development of therapeutic tools. Due to their electrophilic 
nature, the best known mechanism of action of these mediators is the covalent modification of 
proteins at cysteine residues through Michael addition. Identification of cyPG targets through 
proteomic approaches, including MS/MS analysis to pinpoint the modified residues, is proving 
critical to characterize their mechanisms of action. Among the targets of cyPG are 
proinflammatory transcription factors, proteins involved in cell defense, such as the regulator 
of the antioxidant response Keap1 and detoxifying enzymes like GST, and key signaling 
proteins like Ras proteins. Moreover, cyPG may interact with redox-active small molecules, 
such as glutathione and hydrogen sulfide. Much has been learned about cyPG in the past few 
years and this knowledge has also contributed to clarify both pharmacological actions and 
signaling mechanisms of these and other electrophilic lipids. Given the fact that many cyPG 
targets are involved in or are targets for redox regulation, there is a complex interplay with 
redox-induced modifications. Here we address the modification of protein cysteine residues by 
cyPG elucidated by proteomic studies, paying special attention to the interplay with redox 
signaling. 
Keywords 
Electrophilic lipids, cyclopentenone prostaglandins, Ras proteins, palmitoylation, redox 
regulation. 
 
I. INTRODUCTION 
 
Cyclopentenone prostaglandins (cyPG) are reactive lipid species that are produced within the 
cell and that, upon exogenous administration, have displayed anti-viral, anti-tumoral and anti-
inflammatory effects. Therefore, their use as potential therapeutic agents has placed the 
spotlight on their involvement in pathophysiological processes and their molecular 
mechanisms of action (Stamatakis, Sánchez-Gómez & Pérez-Sala, 2004; Straus & Glass, 2001). 
cyPG are electrophiles that can react with nucleophilic residues of proteins such as cysteine 
residues, hence eliciting conformational changes in these proteins or modifying their binding 
properties. Interestingly, cyPG structure determines the ability to bind to specific cysteine 
residues even within the same protein, giving rise to a molecular selectivity that is reflected in 
4 
 
the cellular processes affected by cyPG action (Garzón et al., 2011; Renedo et al., 2007). For 
instance, cyPG anti-inflammatory effects are achieved through covalent modification and 
inhibition of certain proteins in the NF-κB pathway, while the cellular redox status and stress 
response can be regulated by cyPG binding to redox sensitive proteins (Díez-Dacal & Pérez-
Sala, 2010; Kim & Surh, 2006). It is thus important to pinpoint specific molecular mechanisms 
of cyPG action and study their role in pathophysiology. 
 
A. cyPG Formation 
 
cyPG are generated from membrane fatty acids, especially arachidonic acid which is a 
precursor for other electrophilic lipids via enzymatic and non-enzymatic pathways (Fig. 1). 
Arachidonic acid is first cyclooxygenated and peroxidated by cyclooxygenases (COX) to give 
rise to PGH2, which is further transformed by different prostaglandin synthases to generate 
PGE2 and PGD2, among others (Funk, 2001) (see Figure 1). Formation of these PGs has also 
been reported to occur through the isoprostane pathway in which peroxidation of arachidonic 
acid occurs by non-enzymatic mechanisms generating E/D-ring isoprostanes, which can suffer 
epimerization to yield compounds identical to COX-derived PGE2 and PGD2  (Gao et al., 2003). 
cyPG of the A series are produced by dehydration of PGE2 while J series cyPG arise from 
dehydration of PGD2 (Narumiya & Fukushima, 1985; Ohno et al., 1986; Shibata et al., 2002). 
Upon dehydration, PGD2 gives rise to PGJ2, which can be further dehydrated to yield 15-deoxy-
Δ12,14-PGJ2 (15d-PGJ2) or it can be derived to Δ12-PGJ2 in an albumin-dependent process 
(Shibata, et al., 2002). Dehydration of PGE2 in turn yields PGA2, whereas PGA1 arises by non-
enzymatic dehydration of PGE1, which may derive from dihomo-γ-linolenic acid by means of 
COX enzymes (Levin et al., 2002; Ziboh, Miller & Cho, 2000). 
 
B. Reactivity 
 
The common feature of this wide variety of cyPG is the presence of an α,β-unsaturated 
carbonyl group in the cyclopentane ring conferring a high electrophilicity to the carbon(s) in 
the -β position by which they can suffer the attack of nucleophilic groups, such as thiol or 
amino groups in amino acids, and form Michael adducts (Fig. 1). For cysteine residues the 
reactive species is the thiolate anion. Ionization of cysteine thiols is highly dependent on the 
structure of the surrounding area since the properties of surrounding residues can affect the 
pKa of cysteines (Mossner, Iwai & Glockshuber, 2000). In general, cysteines with a low pKa 
would be more reactive, with those located in a low pH environment favouring the formation 
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of more stable cyPG adducts (Bickley et al., 2004). Steric hindrances or exposure to the cellular 
milieu can also influence the formation of adducts. In addition, the presence of distinctive 
structural features in cyPG confers selectivity to their binding to cellular proteins to elicit their 
effects. 
cyPG belong to an extended family of lipid electrophiles, which are generated in low 
amounts under basal conditions but increase upon oxidative stress (Ceaser et al., 2004; 
Koenitzer & Freeman, 2010). In situations associated with increased generation of reactive 
oxygen or nitrogen species, as in inflammation, unsaturated lipids prone to oxidation, like the 
polyunsaturated fatty acids present in biological membranes, in addition to their enzymatic 
transformations, can suffer various non-enzymatic oxidations, giving rise to highly varied 
structures including the reactive aldehyde 4-hydroxynonenal or nitro-fatty acids. Many of 
these reactive species may coexist in the cell at a given time and exert biological actions due to 
alkylation of biological molecules. One general problem of the work with these compounds is 
their detection and quantitation, hampered in part by their high reactivity. Controversy has 
accompanied the study of both cyPG and nitro fatty acids since the concentrations used in 
most biochemical or pharmacological studies are in the micromolar range whereas 
concentrations measured in biological systems are lower, in the picomolar to nanomolar range 
depending on the reports (Garzón et al., 2011; Schopfer, Cipollina & Freeman, 2011; Tsikas et 
al., 2009). Conversely, the stability of cyPG binding to proteins has fostered their use in 
proteomic studies. The wealth of information gathered through these studies is paving the way 
to unveil the mechanisms of action and targets of other electrophilic mediators recently 
identified. 
 
C. Biological Actions of cyPG 
 
The biological effects of cyPG binding to proteins involved in numerous cellular processes have 
been studied both in vitro and in vivo, highlighting the large number of pathways that can be 
targeted by these compounds. One of the most widely studied roles of cyPG is their regulation 
of inflammation. For instance, 15d-PGJ2 blocks the induction of several genes such as iNOS, 
COX-2 or ICAM-1 that are upregulated by proinflammatory signals, reduces inflammatory 
cytokine release and inhibits monocyte trafficking via cell adhesion molecules (Gilroy et al., 
2004). The anti-inflammatory potential of cyPG relies heavily on their ability to inhibit 
important proinflammatory transcription factors such as NF-κB and AP-1 and/or to activate 
transcription factors of the PPAR family or Nrf2. Though these compounds are generally 
regarded as anti-inflammatory mediators, cyPG have also been shown to exert 
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proinflammatory effects in certain settings, as in the activation of eosinophils and Th2 
lymphocytes (Gazi et al., 2005; Monneret et al., 2002). A dual effect of cyPG has also been 
observed regarding cellular redox status and the electrophilic response. On one hand, 
oxidative stress may be induced by cyPG at mitochondria or by acting on other ROS producers 
such as NADPH oxidase, giving rise to potential protein oxidation (Landar et al., 2006c; 
Martinez, Perez-Castillo & Santos, 2005; Shin et al., 2009). On the other hand, cyPG activation 
of the transcription factor Nrf2 induces the expression of antioxidant response-related genes. 
Interestingly, 15d-PGJ2 has been observed to exert biphasic effects on cellular GSH content and 
on cytokine-elicited induction of proinflammatory genes, depending on the levels present of 
this cyPG and in correlation with the activation of an antioxidant response (Levonen et al., 
2001; Martínez et al., 2012). 
 The biphasic nature of cyPG is also reflected by their role in proliferation, 
tumorigenesis and apoptosis. Initially, cyPG were described as anti-proliferative and pro-
apoptotic agents in cancer cells and animal models. Their anti-proliferative behaviour was 
related to multiple antineoplasic mechanisms such as blocking cell cycle progression, inducing 
oxidative stress or activating the mitochondrial apoptotic pathway (Kamagata et al., 2007; Kim 
et al., 1993; Kondo et al., 2001; Nencioni et al., 2003). However, some studies have reported 
an induction of mouse skin tumorigenesis mediated by 15d-PGJ2 (Millán et al., 2006) as well as 
an inhibitory role on the tumor suppressor transcription factor p53, potentially promoting 
tumor growth (Kim et al., 2010). It has also been observed that cyPG have anti-viral effects by 
inducing stress responses and the expression of heat shock proteins (e.g. Hsp70), by inhibiting 
viral replication factors such as NF-κB and through direct binding to viral proteins (Kalantari et 
al., 2009; Santoro, 1997). The biological effects of cyPG depend heavily on their concentration, 
cellular context, and specific target proteins in cells or tissues. Therefore, as described above, 
cyPG can act as dual mediators similarly to other redox regulators like NO, modifying 
numerous cellular processes. 
 
D. Mechanisms of Action 
 
cyPG are able to exert their effects by targeting a plethora of proteins, though the nature of 
the interaction can vary. Most cyPG targets have been identified by proteomic studies 
performed in conditions under which labile interactions are lost. Therefore, covalent protein-
cyPG adducts have been more widely studied and many target cysteines have been identified 
(though histidine residues can also bind cyPG covalently- see (Yamaguchi et al., 2010)). 
Depending on the chemical properties of the cyPG, i.e. one (single enones) or two (dienones) 
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electrophilic carbons, these reactive lipids will bind to free cysteine residues in specific protein 
regions that sterically allow cyPG access. In fact, some cyPG with two electrophilic moieties 
have been shown by protein fingerprinting to bind simultaneously to two cysteine residues of 
the same or different proteins (Oeste et al., 2011; Pérez-Sala, Cernuda-Morollón & Cañada, 
2003). 15d-PGJ2 binds covalently to transcription factors such as PPARγ or NF-κB (Cernuda-
Morollón et al., 2001; Shiraki et al., 2005), cytoskeletal proteins including actin or vimentin 
(Stamatakis, Sánchez-Gómez & Pérez-Sala, 2006) and redox-regulated proteins like H-Ras, 
Keap1 or GSTP1-1 (Levonen et al., 2004; Oliva et al., 2003; Sánchez-Gómez et al., 2007), as it 
will be discussed further below. However, cyPG also interact non-covalently with proteins such 
as PG membrane receptors or soluble carrier proteins like albumin (Gazi, et al., 2005; 
Yamaguchi, et al., 2010). DP2, one of the receptors for PGD2, is a G-protein-coupled receptor 
expressed in several leukocytes that participates in chemotaxis and allergic inflammation (see 
(Sandig, Pease & Sabroe, 2007) for review). The cyPG 15d-PGJ2 and Δ12-PGJ2 are ligands for this 
receptor (Sawyer et al., 2002), though the effects produced by DP2 activation vary in different 
models and warrant further studies. Interestingly, both covalent and non-covalent modes of 
interaction of cyPG with other proteins, including GSTP1-1 (Paumi et al., 2004; Sánchez-
Gómez, et al., 2007) and PGES1 (Prage et al., 2012) have been detected, showing the 
multivalent binding nature of these electrophiles. 
 
E. Therapeutic Potential 
 
Many exogenous and endogenous stimuli elicit inflammatory responses, so cytoprotective 
mechanisms are essential to maintain cellular homeostasis. Various endogenous electrophiles 
have been identified as mediators of protective pathways, like the antioxidant response or the 
resolution of inflammation, thus presenting therapeutic opportunities (Gilroy et al., 1999; Itoh 
et al., 2004; Rajakariar et al., 2007). In this context, 15d-PGJ2 has been shown to ameliorate 
several pathological processes. Through the inhibition of NF-κB, this cyPG shows protective 
properties against ischemic acute renal failure in rats (Chatterjee et al., 2004). Inhibition of NF-
κB together with AP-1 and activation of PPARγ are possible mechanisms of protection against 
multiple-organ failure and systemic inflammation caused by endotoxic shock (Dugo et al., 
2004; Zingarelli et al., 2003). 15d-PGJ2 also shows protective effects against gastrointestinal 
damage by reducing the production of proinflammatory cytokines and iNOS expression 
(Cuzzocrea et al., 2003). Cardiovascular function may also be preserved through cyPG action, 
such that a cyPG-liposome formulation known as “LipoCardium” has been shown to reduce 
vascular lesions derived from atherosclerosis in mice (Homem de Bittencourt et al., 2007). 
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Regarding tumorigenesis, cyPG have shown pro-apoptotic and/or anti-proliferative effects in 
tumor cells and other in vivo models (Kato et al., 1986; Sasaki et al., 1999). However, this 
process is highly dependent on the experimental model, for there are instances in which cyPG 
may potentiate tumor growth (Kim & Surh, 2008; Millán, et al., 2006). A similar dual effect of 
cyPG has been observed in the nervous system, where both neuroprotective and neurotoxic 
effects can be elicited by prostaglandins of the A series (Qin et al., 2001; Yan et al., 2005; 
Zhang et al., 2008). For example, the mouse model for multiple sclerosis (experimental 
autoimmune encephalomyelitis) showed improvement after treatment with 15d-PGJ2 (Diab et 
al., 2002) and this cyPG also inhibited beta-amyloid-derived proinflammatory responses and 
neurotoxicity (Combs et al., 2000). However, 15d-PGJ2 may give rise to protein aggregation 
resulting in neurodegenerative symptoms in mice (Pierre, Lemmens & Figueiredo-Pereira, 
2009). Therefore, though cyPG have been studied as chemopreventive and protective agents 
against chronic inflammatory pathologies, their systemic effects are varied and context-
dependent, so further studies are needed to establish their therapeutic potential. 
In this context, proteomic approaches provide valuable tools for the comprehension of 
cyPG-elicited cellular processes. Both, identification of cellular targets for covalent 
modification and assessment of protein expression changes or other posttranslational 
modifications elicited by treatment with these compounds may provide important clues on the 
pathways modulated by cyPG and the mechanisms underlying their beneficial or deleterious 
effects. 
 
II. PROTEIN TARGETS OF CYCLOPENTENONE PROSTAGLANDINS 
 
The modification of protein targets by cyPG has been shown to occur largely through Michael 
addition at cysteine residues. Reactive cysteines targeted by cyPG are often involved in redox 
regulation, either because they are susceptible to modification by oxidation or electrophilic 
compounds or because they actively participate in redox catalysis (Kansanen, Kivela & 
Levonen, 2009; Shibata et al., 2003).  Indeed, redox-related proteins often contain nucleophilic 
cysteines with particularly low pKa. In fact, in the cyPG field, some targets have been identified 
through a hypothesis-driven approach, exploring the potential modification of proteins 
previously known to undergo cysteine oxidation through various mechanisms, like thiolation or 
formation of sulfenic acid, as in the case of c-Jun (Pérez-Sala, Cernuda-Morollón & Cañada, 
2003). Conversely, in some cases, the identification of novel protein targets for modification by 
cyPG has led to unveil their role in redox regulation. Many targets of cyPG identified through 
the use of proteomic approaches have been listed in recent reviews (Garzón, et al., 2011). In 
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this work we will focus on those targets playing an important role in or being regulated by 
cellular redox status. 
Cysteine residues targeted by cyPG are also generally susceptible to modification 
induced by other agents. Some cyPG targets have been shown to be nitrosylated, 
glutathionylated or be involved in disulphide formation under conditions of oxidative stress. In 
some cases the functional consequences of these various modifications are similar, as in the 
case of the cysteine residues present in the DNA binding domains of NF-κB p50 or c-Jun, for 
which modification by various agents, including cyPG, results in inhibition of DNA binding 
(Cernuda-Morollón, et al., 2001; Pérez-Sala, Cernuda-Morollón & Cañada, 2003; Pineda-Molina 
et al., 2001). However, in other cases the structure of the modifying agent appears to be 
important for the functional outcome. There are several examples of this in the literature, 
including transcription factor PPARγ. It has been described that several electrophilic lipids can 
bind to a cysteine residue present in the ligand binding domain of PPARγ. However, not all of 
them produce an effective activation (Waku et al., 2009; Zorrilla, Garzón & Pérez-Sala, 2010). 
Similarly, as it will be discussed below, H-Ras proteins possess several cysteine residues that 
can also be targeted by various oxidative modifications, including glutathionylation and 
addition of various electrophiles with diverse functional consequences. Another example of 
the structure-function relationships of electrophilic or oxidative modifications is provided by 
enzymes of the aldo-keto reductase (AKR) family. Various members of this family possess a 
cysteine residue close to the active site, which is important for function and for the interaction 
of inhibitors. In the case of aldose reductase or AKR1B1, modification of this residue has been 
reported to lead to functional consequences depending on the nature of the modification, 
thus, whereas alkylation by iodoacetatic acid (Liu et al., 1993), acrolein or S-nitrosylation 
(Srivastava et al., 2003) have been reported to increase AKR1B1 catalytic activity, modification 
by HNE (Del Corso et al., 1998) or glutathionylation (Srivastava, et al., 2003) appear to cause 
the inactivation of the enzyme. We have observed that cyPG, in particular PGA1, binds 
covalently to Cys299 in AKR1B10, potentially docking at the active site, and this causes 
inactivation of the enzyme. Similarly, other electrophilic compounds with cyclopentenone 
structure, including cyclopentenone isoprostanes inactivate the enzyme. However, the 
compound cyclopentenone, which does not possess the lateral chains of the PG does not 
inhibit enzymatic activity (Díez-Dacal et al., 2011). Therefore, the size and/or the orientation of 
the interacting molecules may be important for the impairment of catalytic activity. 
Interestingly, as for other enzymes with metabolic activity towards compounds containing α,β-
unsaturated carbonyls, such as glutathione transferases (see below), a reciprocal relationship 
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may exist between various Michael acceptors, including cyPG, and AKR enzymes. Whereas 
cyPG or HNE can inhibit various AKR, some enzymes of this family have been shown to 
metabolize these molecules and/or cyPG precursors, thus reducing their bioavailability and 
biological effects (Byrns et al., 2010; Shen et al., 2011). 
 
A. Ras Proteins 
 
Though ROS production and subsequent protein oxidation was commonly regarded as a toxic 
cellular event, numerous studies have now shown that many proteins can regulate and be 
regulated by redox switches and pathways. Such is the case of Ras proteins, which contain 
cysteine residues that can undergo oxidative modifications which will affect signal 
transduction. Ras proteins possess a common cysteine residue, Cys118, located at the GTP 
binding site. It was observed early on that Ras is activated in cells treated with redox 
modulating agents and as such is a key transmitter of redox stress signals (Lander et al., 1997). 
S-Glutathionylated and S-nitrosylated forms of H-Ras are detected in vitro and in cells when 
the protein is exposed to thiol oxidants such as hydrogen peroxide or S-nitrosoglutathione, 
respectively (Mallis, Buss & Thomas, 2001). The structural and functional consequences of 
nitrosylation of Cys118 have been studied in detail proposing a radical-based mechanism that 
stimulates guanine nucleotide exchange (Heo et al., 2005). Moreover, oxidative 
posttranslational modifications of cysteine thiols of Ras associated with redox modulation of 
activity has been studied in vitro using isotope-coded affinity tags and mass spectrometry (MS) 
(Sethuraman et al., 2007). Of the three Ras proteins, H-Ras differs from other Ras proteins (N- 
or K-Ras) especially at its C-terminus, which contains three cysteine residues (Cys181, Cys184 
and Cys186), of which, Cys186 is the isoprenylation site whereas Cys181 and Cys184 are sites 
for palmitoylation (Hancock et al., 1989) and suffer lipidation cycles involved in protein 
localization and activation (Pérez-Sala, 2007; Rocks et al., 2005). Interestingly, in cells, 
glutathionylation of H-Ras has been reported to exert different functional consequences 
depending on the target cysteine: whereas glutathionylation of Cys118 has been reported to 
increase Ras activity due to nucleotide exchange (Clavreul et al., 2006a) glutathionylation of 
the C-terminal cysteines has been shown to interfere with palmitoylation altering Ras 
subcellular localization and favoring apoptosis (Burgoyne et al., 2012). In contrast, guanylation 
of Cys184 correlates with H-Ras activation at the plasma membrane (Nishida et al., 2012). 
Redox regulation of Ras has been proposed to play a role in pathophysiology, including 
atherosclerosis, in association with oxLDL generation (Clavreul et al., 2006b) and metabolic 
stress (Burgoyne, et al., 2012). Other proteins of the Ras superfamily may also be subject to 
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redox regulation depending on the modified agent and the targeted cysteine(s) (Heo et al., 
2006). 
Ras proteins are also selectively modified by lipid electrophiles with different 
structures, such as cyPG, that elicit conformational changes which in some cases lead to 
activation of these small GTPases (Oliva et al., 2003; Renedo et al., 2007). cyPG bind covalently 
to Ras proteins both in vitro and in cells in a highly selective manner that depends on cyPG and 
protein structure. The electrophile moiety of particular cyPG, i.e. single enones or dienones, 
produce distinct binding patterns according to the Ras isoform they modify (Renedo et al., 
2007). Using MALDI-TOF MS it was observed that single enone cyPG (e.g. PGA1 and PGA2) 
formed multiple adducts with H-Ras and bound mostly to the cysteine residue in the GTP-
binding domain (Cys118). In contrast, modification by 15d-PGJ2 mapped specifically at the C-
terminal region of the protein (Oliva et al., 2003). Combination of proteomic and mutagenesis 
studies identified Cys184 as the residue required for 15d-PGJ2 binding. Further studies showed 
that 15d-PGJ2 and ∆12-PGJ2, being bifunctional PG, could simultaneously bind to Cys181 and 
Cys184, inducing intra-molecular cross-linking (Garzón et al., 2011; Oeste et al., 2011). 
Considering the differences amongst Ras proteins, this selective modification gives rise to 
specific activation patterns of H-, K- and N-Ras according to the cyPG structure (Renedo et al., 
2007). Interestingly, contrary to the redistribution elicited by glutathionylation of Cys181 or 
Cys184, cyPG modification of H-Ras at its C-terminus is associated with activation at the 
plasma membrane. Remarkably, modification of Cys181 and Cys184 by other cysteine cross-
linking agents with cyclic structure such as phenylarsine oxide or dibromobimane is associated 
with H-Ras activation at endomembranes (Oeste et al., 2011). Some of the structure-function 
relationships of the modification of H-Ras C-terminal cysteines by various species are 
summarized in Fig. 2. Therefore, oxidative or cyPG modifications of Ras proteins present yet 
another level of complexity for the regulation of these crucial cell signalling components. 
 
B. The Keap1-Nrf2 System 
 
The regulation of the stability of transcription factor Nrf2 by its partner Keap1 is one of the 
best examples of regulation of a biological function through modification of cysteine residues. 
Keap1 is a cysteine-rich protein which interacts with Nrf2 regulating its degradation and thus 
its cellular levels and function. Several models have been proposed to explain the complex 
regulation of the Keap-Nrf2 system. According to recent interpretations, Nrf2 is bound to 
Keap1, which in turn functions as an adaptor for the ubiquitin ligase complex Cul3. Under basal 
conditions, this interaction results in the constitutive ubiquitination and degradation of Nrf2. 
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Under conditions of oxidative or electrophilic stress, modification of cysteine residues in Keap1 
induce conformational changes which disrupt Nrf2 ubiquitination either by a partial 
detachment of the Nrf2-Keap1 complex or by dissociation of the Cul3-Keap1 interaction. This 
results in stabilization of Nrf2 and increased binding to the antioxidant response elements in 
the promoters of its target genes including GSTP1-1, γGCS, several members of the aldo-keto 
reductase (AKR) family, hemooxygenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (see 
(Hayes et al., 2010; Zhang, 2010) for review). 
Keap1 possesses 27 cysteine residues, which appear to be selectively modified by 
several electrophilic agents or oxidative stress. Various experimental approaches have been 
employed to elucidate the chemical mechanisms controlling Keap1 function. In vivo models 
with Keap1 mutants have mapped Cys151, Cys273 and Cys288 as functionally important 
residues. In addition, proteomic analyses have been performed with purified Keap1 from 
various origins. Different electrophiles appear to target diverse cysteine residues for which a 
classification in several categories has been proposed (Kobayashi et al., 2009). 
cyPG bind to Keap1 and activate Nrf2. Activation of Nrf2 by cyPG appears to play an 
important role in cyPG effects, since it has been reported that Nrf2 is required for the anti-
inflammatory actions of 15d-PGJ2 in some experimental systems (Itoh et al., 2004; Lin et al., 
2012). Although the mechanisms involved are not completely elucidated, the Nrf2-dependent 
induction of γGCS leading to GSH synthesis has been reported to mediate 15d-PGJ2 anti-
inflammatory actions through the glutathionylation and inhibition of proinflammatory proteins 
like NF-κB (Lin et al., 2012). Moreover, the Nrf2-dependent induction of HO-1, which itself 
exerts anti-inflammatory actions, has been used as a readout for the biological effects of 15d-
PGJ2 (Oh et al., 2008). Using purified mouse Keap1 and MS analysis, adducts of 15d-PGJ2 with 
Cys273 and 288 and of PGA2 with Cys273, 297 and 489 have been reported (Kobayashi et al., 
2009). However, other cysteine residues may be involved in binding of cyPG to Keap1 
(Kansanen, Kivela & Levonen, 2009). Similarly, it is not yet clear which residues are those 
functionally important for cyPG effects. It seems clear that Cys151 is dispensable for Keap1 
modulation of Nrf2 levels in response to 15d-PGJ2 (Takaya et al., 2012). In zebrafish embryo, a 
Cys288Ser mutant has been shown to retain function and the ability to respond to 15d-PGJ2. 
Therefore, further studies are needed to elucidate the nature of cyPG-Keap1 interactions.  
 
C. GSTP1-1 
 
Interactions of cyPG with enzymes of the GSH biotransformation system, particularly with 
glutathione S-transferases (GSTs), have long been recognized. GSTs are involved in the 
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detoxification of numerous endogenous and exogenous electrophiles through their 
conjugation with GSH, thus favoring their export from cells. In the case of GSTP1-1, an isoform 
related to tumorigenesis and chemoresistance, the interactions with cyPG may be multiple 
because cyPG may be both substrates and inhibitors of this enzyme. Both covalent and non-
covalent modes of inhibition have been reported (Paumi et al., 2004; Sánchez-Gómez et al., 
2007) (Fig. 3). The covalent modification of GSTP1-1 by 15d-PGJ2, observed by MALDI-TOF MS, 
leads to enzyme inactivation, which appears to be irreversible under physiological conditions 
(Sánchez-Gómez et al., 2007). Interestingly, the nature of the interaction of cyPG with GSTP1-1 
appears to depend on the structure of the PG. cyPG with dienone structure induce an 
irreversible oligomerization of GSTP1-1, both in vitro and in intact cells, which requires the 
presence of Cys101 (Sánchez-Gómez et al., 2010). These observations are important because 
Cys101 is present in the human but not in the murine enzyme, in which many studies on the 
response of GST to electrophiles have been performed. However, the residues involved in the 
oligomerization have not been identified by MS and the available evidence comes from the use 
of mutants. Interestingly, the pattern and structural features of 15d-PGJ2-induced 
oligomerization shows similarities with that induced by treatment with H2O2, but not by other 
oxidants like HNE or diamide. However, only dienone cyPG-induced oligomerization was 
resistant under reducing conditions. A summary of the potential interactions of cyPG with 
GSTP1-1 is shown in Fig. 3. 
 
D. Other Redox-Regulated Proteins 
 
Another major sensor of cellular stress, including oxidative stress, is the heat shock pathway. 
Primary players in the heat shock response are the heat shock factors (HSF), transcription 
factors which control the expression of diverse cell defense genes including heat shock 
proteins (Hsp) like Hsp70, Hsp90 and the small Hsp (Westerheide & Morimoto, 2005). In a 
simplified view, under resting conditions, HSF1 is in an inactive monomeric form bound to 
Hsp90. However, upon stimulation, HSF1 dissociates from Hsp90 and forms trimers which bind 
to the response elements on the promoters of the target genes (Zhang et al., 2011). HSF is 
activated by thermal stress, redox changes and electrophiles (Ianaro et al., 2003; Morimoto & 
Santoro, 1998). Cysteine modification of HSF or of its negative regulators may lead to HSF 
activation. Thus, many compounds can activate both HSF and Nrf2-dependent responses. In an 
elegant recent study, Zhang et al. have dissociated both pathways by means of MEFs from HSF, 
Nrf2 or Keap1 KO mice, concluding that induction of Hsp70 by activators of the Keap1/Nrf2 
pathway is independent from Nrf2 (Zhang et al., 2011). Interestingly, cyPG have been long 
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known to activate HSF and induce the expression of Hsp (Amici et al., 1992). Although HSF has 
not appeared among the identified cyPG targets, Hsp90 has been found in proteomic studies 
using biotinylated cyPG combined with either 2D electrophoresis and MALDI-TOF MS 
(Stamatakis, Sánchez-Gómez & Pérez-Sala, 2006) or avidin chromatography and LC-MS/MS 
(Garzón et al., 2010; Gharbi et al., 2007). Covalent modification of Hsp90 by PGA1-B has also 
been demonstrated in vitro (Garzón et al., 2010), although the residues involved in the 
modification have not been elucidated. Modification of Hsp90 could disrupt the interaction 
with HSF, resulting in its activation. In addition, several heat shock proteins, including Hsp70, 
71 and 60 have been found retained on avidin after treatment of murine fibroblasts or 
mesenteric vessels with biotinylated cyPG and identified by LC-MS/MS (Charles et al., 2011; 
Garzón et al., 2010). Taken together these results indicate that cyPG may interact with the 
heat shock response pathway at several levels, which may contribute to the protective and 
anti-inflammatory effects of these compounds (Ianaro et al., 2003). 
 Other cyPG targets sustaining the interplay with redox signaling are shown in Table 1. 
 
III. INTERACTIONS OF cyPG WITH REDOX-ACTIVE SMALL MOLECULES 
 
In addition to binding to proteins, cyPG, like other electrophilic molecules can interact with 
other redox mediators or with thiol-containing molecules like glutathione (GSH). This may 
influence the fate of cyPG and their ability to interact with proteins. cyPG have been shown to 
form adducts with GSH, both enzymatically and non-enzymatically. A single adduct resulting 
from the in vitro reaction of 15d-PGJ2 with GSH was detected by electrospray MS and 
characterized by NMR showing to involve C9 of the PG (Paumi et al., 2003). A similar adduct 
was also formed in cells. In an earlier study, a single adduct of 9-deoxy-∆9,∆12(E)-prostaglandin 
D2 was observed by fast atom bombardment MS to form with GSH through C9 in vitro, and a 
GSH adduct was detected in vivo after administration of radioactive cyPG to rats. In this case, a 
bis-adduct was also observed under prolonged incubations of GSH with excess PG (Atsmon et 
al., 1990), although it is not known whether bis-adducts can be formed in cells. CyPG-GSH 
adducts may be exported from cells through MRP transporters (Paumi, et al., 2003), for which 
cyPG adduct formation is considered as a mechanism for detoxification and attenuation of 
cyPG effects (Díez-Dacal & Pérez-Sala, 2012). However, it is not yet clear whether CyPG-GSH 
adducts may display biological activity. In fact, certain cyPG-cysteine adducts have been 
reported to inhibit NF-κB activity (Bickley et al., 2004). CyPG-GSH adducts are reversible and 
display different stability depending on the cyPG structure, with dienone cyPG-GSH adducts 
being less stable, this having consequences on the availability of cyPG for protein modification 
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(Suzuki et al., 1997). Thus, it has also been hypothesized that some soluble thiol-cyPG adducts 
could protect these electrophilic molecules from nucleophiles until they reach a protein 
environment where they would establish more stable adducts (Bickley et al., 2004). 
Interestingly, the interactions between cyPG and GSH are reciprocal, since cyPG may also 
influence GSH availability and metabolism. Recently, 15d-PGJ2 has been proposed to deplete 
intracellular GSH through a cycle involving cellular export of the GSH-15d-PGJ2 conjugate, 
hydrolysis of the conjugate and re-entry of the cyPG (Song et al., 2011). Interestingly, cyPG 
may also influence GSH levels by controlling GSH synthesizing enzymes through Nrf2-mediated 
mechanisms (Levonen et al., 2001). 
15d-PGJ2 may react intracellularly with other small molecule thiols or related species. 
Recently, hydrogen sulfide anion (HS-) generated through the enzymatic action of 
cystathionine-β-synthase and cystathionine-γ-lyase has been reported to react with various 
electrophiles, thus contributing to modulate their reactivity and biological action (Nishida et 
al., 2012). The resulting electrophile-SH adduct can have various fates, including undergoing 
dehydration, oxidation and subsequent desulfhydration or dimerization. In the case of 15d-
PGJ2 nucleophilic addition or substitution of HS- at the electrophilic carbon gave rise to an 
unstable sulfhydrated product, 15d-PGJ2-SH, that was rapidly converted to sulfonated 15d-
PGJ2-SO3H, which has been characterized by LC-MS (Nishida et al., 2012).  
These multiple reactions of 15d-PGJ2 with low molecular weight thiols should be taken 
into account when detecting or quantitating levels of 15d-PGJ2 and potentially other cyPG in 
biological systems. 
 
IV. PROTEIN MODIFICATIONS INDUCED BY cyPG TREATMENT 
 
Exposure of cells to cyPG may cause alterations in GSH metabolism and induce oxidative 
stress. Therefore, other protein modifications, due to the action of ROS or to the secondary 
formation of electrophiles can occur in cells upon treatment with cyPG. Interestingly, MS 
analysis of proteins treated in vitro with cyPG shows a higher occurrence of oxidative 
modifications in several proteins, including GSTP1-1 and H-Ras (Sánchez-Gómez et al., 2007) 
(Oliva et al., 2003). The influence of the presence of the PG in these modifications requires 
further study. In cells, several oxidative modifications have been observed. The occurrence of 
S-thiolation in cells treated with 15d-PGJ2 has been previously demonstrated, and several 
target proteins for this modification, including α-enolase, heat shock proteins and GSTP1-1, 
have been identified through 2D-electrophoresis and MALDI-TOF MS (Ishii & Uchida, 2004). 
Treatment with 15d-PGJ2 also induced protein carbonylation, being the component of the 
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proteasome S6 ATPase the major target identified by biotin-LC-hydrazide derivatization 
followed by 2D-electrophoresis and MALDI-TOF MS of tryptic digests (Ishii et al., 2005). 
Similarly, by using biotinylated iodoacetamide we showed that treatment with 15d-PGJ2 
reduced the free thiol content of cellular proteins (Sánchez-Gómez et al., 2007). In the case of 
cellular GSTP1-1 these modifications included both reversible and irreversible oligomerization 
and induction of a reversible intramolecular disulphide bond (Sánchez-Gómez et al., 2010). In 
addition, increased glutathionylation has been shown to occur in 15d-PGJ2-treated cells (Lin et 
al., 2012). Therefore, the contribution of the various modifications induced directly or 
indirectly by cyPG treatment to the biological effects of these compounds deserves further 
study. In the context of redox and electrophile signaling it is important to consider that there is 
a wide interplay which affects the modification of several redox-active targets. Both direct and 
indirect modifications may affect proteins involved in redox control, including thioredoxin (Trx) 
and Trx reductase, or in the generation of inflammatory mediators, like transcription factors 
such as NF-κB and AP-1, which control COX-2 expression, and thus, the synthesis of cyPG 
precursors. Moreover, the levels and duration of the exposure to cyPG may determine the 
accumulation of adducts in cells leading to an intensification of the biological effect (Oh et al., 
2008). Therefore, for any given target, a mixture of molecular entities resulting from its 
modification by various reactive species may coexist in a cell under cyPG treatment and 
oxidative stress conditions. These various entities may not share completely overlapping 
functions, thus resulting in diverse biological outcomes. As an example, a scheme showing 
some of the species of GSTP1-1 which have been detected in cells treated with 15d-PGJ2 is 
shown in Fig. 3.  
 
V. PROTEOMIC APPROACHES FOR IDENTIFICATION OF cyPG TARGETS 
 
Early studies on the biological effects of cyPG revealed the importance of the reactive 
cyclopentenone moiety for their antiproliferative and antitumoral activity. In studies with 
radioactive compounds it was observed that cyPG accumulated inside cells binding irreversibly 
to some cellular components, in particular, nuclei (Narumiya et al., 1987). The use of 
biotinylated analogs of cyPG which are cell-permeable greatly facilitated the study of the fate 
of these compounds showing their binding to proteins, which is stable under denaturing 
conditions (Cernuda-Morollón et al., 2001; Parker, 1995). Since these early studies, the binding 
of cyPG to proteins has been repeatedly demonstrated both through cellular and in vitro 
approaches. 
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A. Proteomic Studies In Cells Or Cell Fractions 
 
Biotinylated cyPG analogs have constituted essential tools for the identification of cyPG targets 
from cellular models. Figure 4 depicts a classical work flow for the isolation, identification and 
characterization of cyPG protein targets. Early studies used targeted or hypothesis-driven 
approaches to explore the involvement of particular proteins in the effects of cyPG. These 
studies employed whole cell approaches followed by immunoprecipitation of the hypothetical 
targets to assess the presence of a bound biotin moiety (Cernuda-Morollón et al., 2001; Pérez-
Sala, Cernuda-Morollón & Cañada, 2003; Shibata et al., 2003). Complementary approaches 
included pull-down on avidin beads to confirm the presence of the protein of interest in the 
retained fraction. These strategies allowed confirming the modification of various proteins in 
intact cells, including the p50 subunit of NF-κB, transcription factor c-Jun and Trx (Cernuda-
Morollón et al., 2001; Pérez-Sala, Cernuda-Morollón & Cañada, 2003; Shibata et al., 2003). 
Whole cell extracts have been used also for 2D-electrophoresis in duplicate gels used for biotin 
detection and protein staining, respectively, followed by spot excision and protein 
identification by peptide mass fingerprint by MALDI-TOF MS or MALDI-TOF-TOF MS/MS (Aldini 
et al., 2007; Stamatakis, Sánchez-Gómez & Pérez-Sala, 2006). 
cyPG display a subcellular distribution which depends on the structure of the PG and of 
the cell type. Factors like GSH concentration or GST activity may affect the preferential 
distribution of cyPG into cytosolic and nuclear compartments (Straus et al., 2000). Evidence of 
a preferential subcellular localization of these compounds has been obtained by monitoring 
their biological effects or by the use of tagged analogs coupled to fluorescent detection in 
microscopy applications or in cell fractionation studies. Biotinylated cyPG-labeled proteins 
show a distinct distribution between soluble and particulate or nuclear and cytosolic fractions 
that suggests the presence of specific targets (Garzón et al., 2010; Gharbi et al., 2007; Straus et 
al., 2000).  
Soluble and particulate cellular fractions have been used to identify targets of PGA1 
through proteomic approaches involving chromatography on avidin, separation of the retained 
proteins in SDS-PAGE gels and LC-MS/MS analysis of extracts from protein bands subjected to 
trypsin digestion (Garzón et al., 2010; Gharbi et al., 2007). Avidin chromatography provides an 
enrichment step for the targets that facilitates their identification. In addition, other strategies 
have been used, including immunodepletion of interfering abundant proteins in order to 
reveal the proteins of interest (Díez-Dacal et al., 2011). In cytosol-mitochondria fractionations, 
15d-PGJ2-B has been shown to bind preferentially to mitochondrial targets in MDA-MB231 
cells (Diers et al., 2010). Treatment of isolated mitochondria with 15d-PGJ2-B and subsequent 
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enrichment on avidin beads followed by 2D-electrophoresis and peptide mass fingerprinting by 
MALDI-TOF MS, allowed the identification 17 potential targets for 15d-PGJ2 in this organelle, 
including glutamate dehydrogenase, ATP synthase and catalase, which may be involved in the 
induction of permeability transition and cytochrome C release elicited by this cyPG (Landar et 
al., 2006b). Importantly, some of the targets identified in mitochondria like catalase or 
aldehyde dehydrogenase could be involved in the increase in ROS generation and in the 
alterations of cellular redox status elicited by cyPG, contributing to their cytotoxic effects 
(Landar, et al., 2006b). A remarkable approach has been the preparation of a 15d-PGJ2 analog 
specifically targeted to mitochondria through the conjugation with the lipophilic cation 
triphenylphosphonium (TPP). Here, 2D-electrophoresis followed by detection with anti-TPP 
antibody allowed the detection of the modified proteins. Using this approach, 53 and 22 spots 
were found to be unique for 15d-PGJ2-B or TPP detection, respectively, with 10 spots being 
positive for both (Diers et al., 2010). More recently, fluorescent derivatives of arachidonic acid 
have been used for detection of proteins modified by arachidonic acid-derived electrophilic 
lipids either by fluorescence microscopy or SDS-PAGE in rat ventricular myocytes and isolated 
mitochondria (Cummins et al., 2012), which will enable the identification of targets.  
In considering the presence of cyPG targets in defined subcellular fractions, it should 
be noted that cyPG can also alter the subcellular distribution of some of its targets through 
direct or indirect mechanisms, which can influence the results of the proteomic studies. In 
certain cell types, cyPG promote the cytoplasmic retention of transcription factor NF-κB by 
directly inhibiting IKK, and thus, IκBα phosphorylation and degradation (Straus et al., 2000). 
The appearance of protein aggregates in dopaminergic neurons upon in vivo infusion of 15d-
PGJ2 has also been reported (Pierre, Lemmens & Figueiredo-Pereira, 2009). TDP-43 is a nuclear 
protein involved in the neurodegenerative disorder known as TDP-43 proteinopathy 
(amyotrophic lateral sclerosis and frontotemporal lobar degeneration with ubiquitin-positive 
oclusions), where TDP-43 is abnormally accumulated in the neuronal cytoplasm. 15d-PGJ2 has 
been shown to induce alterations in TDP-43 subcellular localization by promoting its 
cytoplasmic localization (Zhang et al., 2010). These effects should be taken into account when 
exploring the effects and targets of cyPG. 
Other strategies used to detect 15d-PGJ2 in specific compartments include the use of 
antibodies, with which an increased signal has been evidenced in the spinal motor neurons in 
amyotrophic lateral sclerosis (Kondo et al., 2002), and in the cytoplasm of foamy macrophages 
in human atherosclerotic plaques (Shibata et al., 2002). However, since this antibody 
apparently detects free 15d-PGJ2, it is not applicable in proteomic studies. Later on, other 
antibodies have been developed against cyPG, including ∆12-PGJ2 and 15d-PGJ2, for use in 
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ELISA (Syeda et al., 2012a; Syeda et al., 2012b). However, to the best of our knowledge they 
have not been used in proteomic studies to date. 
 
B. Proteomic In Vitro Approaches Using Peptides And Proteins 
 
Due to the difficulties in characterizing the sites of cyPG addition in proteins from complex 
biological samples, most proteomic studies to date combine the detection of adducts in cells 
by using tagged cyPG with the analysis of purified proteins or peptides modified in vitro with 
cyPG in order to identify the sites of modification. Thus recombinant or purified proteins have 
been used to confirm and characterize cyPG addition in the case of actin, tubulin, vimentin, H-
ras proteins or Keap-1, among others (Aldini et al., 2007; Cocca et al., 2009; Gharbi et al., 2007; 
Kobayashi et al., 2009; Renedo et al., 2007) (for detailed information on the approaches used 
to characterize cyPG-protein interactions by proteomic methods, please see (Garzón et al., 
2011)). Although this approach is useful it poses some limitations. Protein modification in vitro 
and in the cellular context may not display the same selectivity. For instance, cyPG may 
covalently bind to either Cys47 or Cys101 of GSTP1-1 under in vitro conditions, as observed by 
MALDI-TOF MS (Sánchez-Gómez et al., 2007). In contrast, in intact cells there is a clear 
selectivity for Cys101, as evidenced by the use of GSTP1-1 mutants and biotinylated cyPG 
analogs (Sánchez-Gómez et al., 2010). We have previously shown that the cellular context, and 
in particular the presence of GSH is responsible for the differential modification of proteins by 
15d-PGJ2-B and PGA1-B (Gayarre et al., 2005). Moreover, GSH depletion may favor the 
incorporation of PGA1-B into selective proteins, like the tumor marker AKR1B10 (Díez-Dacal et 
al., 2011). In addition, in the cellular context, steric factors arising from interactions with other 
proteins or the presence of ligands or substrates may affect the accessibility of residues 
targeted by cyPG. In the case of GSTP1-1 for instance, incubation in the presence of non-
hydrolysable GSH analogs reduces the interaction with cyPG, thus pointing to the influence of 
conformational or steric factors. In contrast, in the case of Ras proteins, a similar selectivity of 
cyPG-induced modification has been observed in vitro by MS using recombinant proteins, and 
in cells through the use of mutants. Therefore, it would be important to assess whether the 
cellular context also influences the selective modification of other cellular proteins by 
electrophiles and/or to confirm the sites of modification identified in vitro through studies in 
intact cells. 
For some of the targets identified, as in the case of IKKβ or CRM1 (Hilliard et al., 2010; 
Vunta et al., 2007), after evidencing binding of cyPG to the full-length protein, the site of 
addition has been proposed on the basis of their binding to isolated peptides containing the 
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residues of interest. Strategies using purified peptides do not fully take into account factors 
related to the protein and the cellular context that may influence the site of modification, and 
the results obtained require confirmation using the full-length protein, i.e., through the use of 
site-specific mutants. Still, they may provide some valuable information on specific regions of 
the targets. For instance, in the case of H-Ras, as detailed above, the use of a peptide from the 
hypervariable region of the protein containing the two palmitoylation cysteines was a valuable 
tool to show the ability of cyPG with dienone structure to induce an intra-peptide cross-linking 
that also takes place in the full-length protein (Oeste et al., 2011). 
 
VI. TECHNICAL ISSUES AND STRATEGIES FOR THE PROTEOMIC DETECTION OF cyPG-PROTEIN 
ADDUCTS 
 
In spite of the numerous proteomic studies published in this field, to the best or our 
knowledge, no studies have reported the detection of the adducts formed in cells by 
endogenous or exogenously added cyPG by MS methods, nor the identification of the 
modification sites. All published studies detecting the cyPG-peptide adducts have been 
performed using purified proteins or peptides incubated with the cyPG in vitro, as detailed 
above. In most of these studies, MALDI-TOF(TOF) or various forms of LC coupled to ESI MS/MS 
have been used and most analysis have been performed in the positive mode, detecting 
adducts of 15d-PGJ2 with proteins formed by Michael addition with increments equal to the 
mass of the cyPG (+316.5, +317.5 in the protonated form) (Hilliard et al., 2010; Kim et al., 
2007; Liu et al., 2011; Pérez-Sala, Cernuda-Morollón & Cañada, 2003; Renedo et al., 2007; 
Shibata et al., 2003). In a study on 15d-PGJ2-modified microtubules, in addition to the ion at 
m/z 317.4 Da, corresponding to the monoisotopic, protonated 15d-PGJ2 molecule, an 
increment of +299.4, corresponding to one PG molecule with the loss of one H2O molecule was 
observed and used for precursor ion scanning (Cocca et al., 2009). 
The difficulties to observe cyPG-protein adducts in samples from cells may be due, 
among other reasons, to the low abundance of the modified species or the use of non-optimal 
conditions for LC separation of the modified peptides or for MS analysis. In addition, the 
potential occurrence of protein or peptide cross-links or of additional modifications may 
hamper the identification of the modified peptides. For these reasons, optimization of the MS 
analysis conditions plus a detailed characterization of adducts formed is needed for detection 
of the modified peptides from biological samples. 
It should be also taken into account that certain buffer components may interfere with 
adduct formation or detection. Buffers may contain DTT or HS-. Both molecules can react with 
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cyPG, thus reducing the amount of reactive or detectable cyPG. In addition, when DTT is 
present during the incubation of peptides or proteins with cyPG in vitro, the formation of 
peptide-DTT-cyPG or peptide-cyPG-DTT adducts, in the case of cyPG dienones, may 
theoretically occur. Indeed, after incubation of H-Ras with cyPG in vitro in the presence of DTT, 
peptides are detected compatible with the formation of H-Ras-DTT-cyPG adducts, an example 
of which is shown in Fig. 5. Moreover, although cyPG-protein adducts are considered stable 
under physiological conditions, high concentrations of thiol-containing compounds could affect 
their stability. 
Unlike the scarce information on cyPG-protein adducts formed in cells, adducts of 
other electrophilic lipids with cellular proteins have been detected through various methods. 
Using exogenous biotinylated HNE, site-specific protein adducts have been identified through 
enrichment on avidin followed by LC-MS/MS, affecting residues like Cys328 in vimentin or 
His246 in aldolase A (Chavez et al., 2010). Similarly, GAPDH has been found to be nitro-
alkylated by nitro fatty acids in vivo in red blood cells from healthy donors, by means of LC 
nanospray linear ion trap MS/MS (LTQ), the alkylation occurring at the catalytically active 
Cys149 and His303 (Batthyany et al., 2006). In mitochondria isolated from old rats, 
derivatization of carbonyls with an aldo-keto reactive probe followed by enrichment on avidin 
and LC-MS/MS allowed the identification of various modification sites in mitochondrial 
proteins. Interestingly, some of the target sites appeared modified by diverse species (Chavez 
et al., 2011). 
The combination of cyPG with other cysteine reagents can also provide 
complementary information on their interaction with thiol groups in proteins. In the case of H-
Ras, pre-incubation of the C-terminal peptide containing Cys181 and Cys184 with dienone 
cyPG led to the incorporation of a single cyPG molecule, as detected by MALDI-TOF MS, and 
completely blocked the incorporation of iodoacetamide. In contrast, single enone cyPG 
allowed the simultaneous incorporation of the PG and one carbamidomethyl moiety, whereas 
two carbamidomethyl moieties were observed in the control peptide. These results helped to 
confirm the formation of an intramolecular cross-link by dienone cyPG (Oeste et al., 2011).  
Conversely, once the target cysteine residue for cyPG in a given protein has been identified, 
tagged cyPG have been used as probes for the interaction of other species with the target 
residue using competition assays (Oeste et al., 2011; Zorrilla, Garzón & Pérez-Sala, 2010). In 
addition bifunctional and/or fluorescent cysteine reagents have been used in combination with 
cyPG or other electrophiles to get insight into the nature of protein modification (Oeste et al., 
2011; Sánchez-Gómez et al., 2010). 
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Given the high sensitivity of the avidin-biotin-based detection techniques, the 
proportion of a given protein that is modified in cells, and thus the functional relevance of the 
modification, remains an issue. Several attempts have been made to estimate the proportion 
of adducts formed upon exposure of cells to biotinylated cyPG analogs. Using a semi-
quantitative method based on the use of biotinylated standards the proportion of 15d-PGJ2-B 
bound to protein in endothelial cells was found to be approximately 1.5 pmol of thiol per 
microgram of total protein (Landar et al., 2006a).  In fibroblasts treated with PGA1-B, protein 
elongation factors (EF-1α and EF-2) were amongst the most extensively modified targets as 
estimated from the retention on avidin of a 3-6% of the amount detected in total lysates 
(Garzón et al., 2010). Notably, GSH depletion may increase the modification of certain proteins 
by cyPG, and a 3-fold increase in avidin retention of AKR enzymes (30% of the total 
immunoreactive signal) has been observed in cells incubated with PGA1-B after treatment with 
buthionine sulfoximine (Díez-Dacal et al., 2011). Thus, several strategies can been used to 
modulate the extent of cyPG-protein adducts formation and potentially improve their 
detection. Remarkably, quantitative proteomic approaches have so far not been used to assess 
the extent of protein modification by cyPG in cells. Regarding the functional outcome, it should 
be taken into account that the repercussion of the modification of a given protein may depend 
on its specific function and on the biological context. Thus, inactivation of a small proportion of 
a constitutively active protein may have little impact in the cell. In contrast, activation of even 
a small proportion of an otherwise inactive protein may provoke relevant biological 
consequences. 
In the context of the extensive use of biotinylated cyPG analogs for target detection 
and purification several drawbacks need to be mentioned. The need for the use of stringent 
conditions to minimize non-specific retention in avidin-based matrices has been stressed 
(Landar et al., 2006b). Avidin-biotin interaction is very stable. Therefore, in theory nearly 
denaturing conditions can be used. The use of stringent conditions allowed reducing the 
retention of interacting partners of the direct targets, and therefore, the purification of 
individual components of multiprotein complexes, like the mitochondrial multi-subunit 
electron transfer complex III (Landar et al., 2006b). In lack of direct detection of the modified 
peptides, target validation through complementary strategies is needed, like 
immunoprecipitation followed by detection of the biotin signal associated with the target 
proteins (Garzón et al., 2010; Shibata et al., 2003). 
As deduced from the above, strategies based on the use of tagged cyPG analogs 
present limitations. Therefore, it will be necessary to develop tag-free methods for detection 
of electrophilic lipid-protein adducts. 
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VII. CONCLUDING REMARKS 
 
Cyclopentenone prostaglandins constitute valuable tools to increase our knowledge on the 
signaling and mechanisms of action of electrophilic mediators. On one hand, the stability of 
the Michael adducts of cyPG with proteins has allowed to perform hypothesis-driven or high 
throughput proteomic studies to identify their targets. In addition, their structural variety has 
allowed observing distinct structural requirements for their binding to proteins thus unveiling 
phenomena like the intra and inter-molecular selectivity of the modification and the influence 
of context and steric factors. cyPG establish reciprocal interactions with redox regulation at 
multiple levels and ultimately, at the level of protein modification. The cysteine residues 
targeted by cyPG are often subjected to other redox-induced modifications or to the addition 
of other electrophilic species. Thus, in any given situation, multiple species of every protein will 
coexist bearing different proportions of structurally different modifications, which in some 
cases will lead to different functional outcomes. Moreover, there is a reciprocal regulation 
between cyPG and the synthesis and/or availability of redox-active small molecules. Therefore, 
an additional output of the study of cyPG targets is the identification of previously unknown 
mechanisms for redox regulation. Nevertheless, to understand the complex picture of cyPG 
signaling many challenges remain ahead, including the identification and characterization of 
the proteins modified by endogenously generated cyPG and the interplay of these 
modifications with other electrophilic and oxidative modifications of varied structure and 
stability in the cellular context. Finally, learning how these modifications can be used in the 
fight against disease remains the ultimate goal. 
 
VIII. ABBREVIATIONS 
AKR    aldo-keto reductase 
COX    cyclooxygenases 
cyPG    cyclopentenone prostaglandins 
GSH    glutathione 
γGCS    γ-glutamilcysteine synthetase 
GST    glutathione S-transferase 
HO-1    hemooxygenase-1 
HSF    heat shock factor 
Hsp    heat shock protein 
iNOS    inducible nitric oxide synthase (NOS2) 
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MEF    mouse embryonic fibroblasts 
PPAR    peroxisome proliferator activated receptor 
15d-PGJ2   15-deoxy-∆12,14-prostaglandin J2 
ROS    reactive oxygen species 
Triphenylphosphonium  TPP 
Trx    thioredoxin 
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Table 1 Selected targets for modification by cyclopentenone prostaglandins which illustrate 
the interplay with redox regulated mechanisms 
TARGET PROTEIN RESIDUE MODIFIED cyPG REFERENCE 
Keap1 Cys273 and Cys288 15d-PGJ2 Kobayashi et al., 2009 
AP-1 
Cys269 in c-Jun,        
not identified in c-Fos 15d-PGJ2 Pérez-Sala et al., 2003 
NF-κB p50 Cys62 15d-PGJ2 
Cernuda-Morollón et 
al., 2001 
NF-κB p65 Cys38 15d-PGJ2 Strauss et al., 2000 
Thioredoxin Cys35 and Cys69 15d-PGJ2 Shibata et al., 2003 
Thioredoxin reductase Not identified PGA1 Moos et al., 2003 
H-Ras 
Cys118, Cys181 and 
Cys184 
15d-PGJ2 
and PGA1 
Oliva et al., 2003 
Renedo et al., 2007 
GSTP1-1 Cys47 and Cys101 15d-PGJ2 Sánchez-Gómez 2007 
Hsp90 Not identified 
15d-PGJ2 
and PGA1 
Stamatakis et al., 2006 
Gharbi et al., 2007 
Hsp70 Not identified PGA1 Gharbi et al., 2007 
Catalase Not identified 15d-PGJ2 Landar et al., 2006 
Aldehyde dehydrogenase Not identified 15d-PGJ2 Landar et al., 2006 
Biliverdin reductase A Not identified 15d-PGJ2 Aldini et al., 2007 
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Figure legends 
 
FIGURE 1. Formation of cyPG and covalent binding to proteins through Michael addition. cyPG 
(in shaded ovals) are generated by spontaneous dehydration of their parent PG, which in turn 
are formed by the action of cyclooxygenases on unsaturated fatty acids but also by non-
enzymatic processes like the isoprostane pathway (via epimerization of isoprostanes, 
represented by dashed lines). cyPG possess one or more electrophilic carbons (marked by 
asterisks), which can suffer the attack of nucleophilic groups such as thiol groups in proteins 
and form Michael adducts, as illustrated at the bottom for 15d-PGJ2. 
 
FIGURE 2. Modifications affecting the C-terminal end of H-Ras protein. H-Ras possesses three 
cysteine residues at its C-terminal end (depicted in green). Cys186 is the site for farnesylation, 
which is considered an irreversible modification (depicted in blue). Amino acids shown in grey 
are lost upon farnesylation. Cysteines 181 and 184 are normally the sites for palmitoylation, a 
reversible modification. These cysteine residues are also targets for modification by various 
electrophiles of different structure, which are schematically shown, leading to diverse 
functional outcomes.  
 
FIGURE 3. Modifications induced in GSTP1-1 by treatment with cyPG. GSTP1-1 exists in the 
cytosol as an active homodimer. GSTP1-1 possesses four cysteine residues, Cys14, 47, 101 and 
169, of which, Cys 101 is located towards the dimer interface. Treatment of cells with 15d-PGJ2 
induces oxidative stress resulting in GSTP1-1 thiolation and formation of intra-or inter-
molecular disulphide bonds, either with other GST monomers or small molecule thiols. In 
addition, 15d-PGJ2 induces irreversible protein cross-links both in vitro and in cells, leading to 
the formation of highly stable tetramers. GSH or GSH analogs, like nitrobenzyl glutathione 
(NBG) protect GSTP1-1 from the covalent binding of cyPG which results in inactivation. In 
addition, 15d-PGJ2 may inhibit GSTP1-1 through non-covalent interactions. 
 
FIGURE 4. Typical workflows used for identification and characterization of cyPG targets. 
 
FIGURE 5. Example of the MS analysis of H-Ras proteins incubated in vitro with PGA1 in the 
presence of DTT. A: Peptide mass fingerprint. In bold, peptides for which the MALDI-TOF-TOF 
MS/MS analysis is shown. B: MALDI-TOF-TOF MS/MS analysis of the peptide of m/z 984.48, 
showing a fragmentation pattern indicative of the incorporation of a PGA1 molecule into the 
peptide CDLAAR (m/z=648.31). Adapted with permission from Renedo et al., (2007) 
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Biochemistry 46:6607-6616. Copyright  2007 American Chemical Society. C:  MALDI-TOF-TOF 
MS/MS analysis of the peptide of m/z 1136.49, showing a fragmentation pattern compatible 
with the incorporation of one DTT (mass 152.2) plus one PGA1 (mass 336.5) molecule into the 
CDLAAR peptide.  
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